Clinical studies of PD-1/PD-L1 blocking antibodies with patient stratification according to the PD-L1 expression at the tumor site showed a higher overall and relapse free survival, as well as a greater number of responses to therapy in patient groups with a higher biomarker level (45). This evidence concerns the gene PDCD1 and neoplasm.